M&A Deal Summary |
|
|---|---|
| Date | 2014-10-27 |
| Target | Eli Lilly - Sentinel and Spectrum Brands |
| Sector | Life Science |
| Buyer(s) | Virbac |
| Sellers(s) | Lilly |
| Deal Type | Divestiture |
| Deal Value | 410M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1968 |
| Sector | Healthcare Services |
| Employees | 4,907 |
| Revenue | 1.2B EUR (2022) |
Virbac is an veterinarian independent pharmaceutical company. Virbac was founded in 1968 and is based in Carros, France.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 5 |
| Sector (Life Science) | 3 of 4 |
| Type (Divestiture) | 2 of 2 |
| State (Indiana) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2014) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2012-11-23 |
Centrovet Laboratories
Cerrillos, Chile Centrovet Laboratories, Inc. specializes in the development and manufacture of salmon and trout vaccines. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-05-13 |
Virbac SA - SENTINEL U.S. Rights
New Jersey, United States Virbac SA - SENTINEL U.S. Rights comprises two canine products Sentinel Flavor Tabs and Sentinel Spectrum which provides protection against 5 different kinds of parasites. |
Sell | $400M |
| Category | Company |
|---|---|
| Founded | 1876 |
| Sector | Life Science |
| Employees | 39,000 |
| Revenue | 28.5B USD (2022) |
Lilly and Company discovers, develops, manufactures, and markets products in two business segments—human pharmaceutical products and animal health products. The mission of its human pharmaceutical business is to make medicines that help people live longer, healthier, more active lives. Most of the products Eli Lilly sells were discovered or developed by its own scientists, and the Company's success depends to a great extent on its ability to continue to discover, develop, and bring to market innovative new medicines. Eli Lilly's animal health business, operating through its Elanco division, develops, manufactures, and markets products for both food animals and companion animals. Eli Lilly manufactures and distributes its products through facilities in the US, Puerto Rico, and 11 other countries. Eli Lilly was originally incorporated in 1876 and is based in Indianapolis, Indiana.
| DEAL STATS | # |
|---|---|
| Overall | 8 of 9 |
| Sector (Life Science) | 3 of 3 |
| Type (Divestiture) | 7 of 8 |
| State (Indiana) | 4 of 5 |
| Country (United States) | 8 of 9 |
| Year (2014) | 1 of 1 |
| Size (of disclosed) | 2 of 5 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-04-22 |
Novartis Animal Health
Basel, Switzerland Novartis Animal Health, Inc. offers innovative, high-quality medicines to improve the quality of life, health and welfare of animals around the world. For pets, the Company's products offer effective aids to treat some internal and external parasites, prevent heartworm and flea infestations and treat ailments such as arthritic pain and kidney, heart and allergic diseases. For farm animals, Novartis Animal Health offers therapeutic products to treat parasitic and bacterial diseases and are also continually developing new vaccines to prevent diseases in livestock and farmed fish. |
Buy | $5.4B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-10-09 |
Locemia Solutions - Phase III Intranasal Glucagon
Quebec, Canada Locemia Solutions - Phase III Intranasal Glucagon is a potential treatment for severe hypoglycemia in people with diabetes treated with insulin. Intranasal glucagon uses a proprietary glucagon nasal powder formulation that is delivered in an emergency situation using a single-use, ready-to-use device. The caregiver presses a small plunger on the bottom of the device to release the glucagon as a puff in the nose, where the glucagon is absorbed in the nasal passages. |
Buy | - |
